Exiqon Presents Data Supporting Use of PCR-Based miRNA Assay as Blood-Based Colon Cancer Dx

The findings suggest that it is feasible to use Exiqon's test to distinguish early-stage colorectal cancer patients from healthy subjects using a single plasma sample comprising less than 1 mL of blood.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.